Citigroup - Mylan "buy"

http://www.ariva.de/news/...-Auch-US-Konkurrent-Mylan-legt-zu-5021098 GrB  

http://www.ariva.de/news/...d-Diluted-EPS-Increases-6-to-0-66-5021900 GrB  

Health Care Conference
09:01 09.05.14

PR Newswire

PITTSBURGH, May 9, 2014


PITTSBURGH, May 9, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the BofA Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014, in Las Vegas. The presentation is scheduled to begin at 11:20 a.m. PT.

Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at http://mylan.com/investors.An archived version will also be available following the live presentation and can be accessed at the same location for a limited time.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.


Quelle: PR Newswire  

Mylan Launches Generic Zyprexa Zydis® Tablets
07:30 14.05.14

PR Newswire

PITTSBURGH, May 14, 2014

PITTSBURGH, May 14, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Olanzapine Orally Disintegrating Tablets (ODT), 5 mg, 10 mg, 15 mg and 20 mg, the generic version of Eli Lilly and Company's Zyprexa Zydis® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of schizophrenia or the acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder.(1)

Mylan
Olanzapine ODT, 5 mg, 10 mg, 15 mg and 20 mg, had U.S. sales of approximately $120.8 million for the 12 months ending March 31, 2014, according to IMS Health.

Currently, Mylan has 300 ANDAs pending FDA approval representing $105.3 billion in annual brand sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $25.4 billion in annual brand sales, for the 12 months ending Dec. 31, 2013, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

(1) There is an increased risk of death in elderly patients with dementia-related psychosis. Olanzapine is not approved for the treatment of patients with dementia-related psychosis. Close supervision of high-risk patients should accompany drug therapy when using in combination with fluoxetine. Other risks include neuroleptic malignant syndrome, increased blood sugars, increased blood lipids, tardive dyskinesia, low blood pressure, white blood cell abnormalities, seizures, impaired judgment, and elevated prolactin levels.

Logo - http://photos.prnewswire.com/prnh/20140423/77793

SOURCE Mylan Inc.


Quelle: PR Newswire  

http://www.ariva.de/news/...ler-Mylan-stemmt-Milliardenzukauf-5099378 GrB  

http://www.ariva.de/news/...eschaefte-an-Konkurrent-Mylan-los-5099445 GrB  

http://www.ariva.de/news/...ott-Geschaeftsbereich-Spezial-und-5101903 GrB  

Mylan Wins Motion for Temporary Restraining Order Against Apotex for Authorized Generic of Paxil® CR
13:07 23.07.14

PR Newswire

PITTSBURGH, July 23, 2014

PITTSBURGH, July 23, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of New Jersey granted its motion for a temporary restraining order against Apotex Inc. and Apotex Corporation in litigation relating to Paroxetine CR, the authorized generic of GlaxoSmithKline's Paxil® CR. The District Court ordered Apotex to immediately discontinue all sales and supply of Paroxetine CR. Mylan previously obtained an order enjoining GlaxoSmithKline from supplying Paroxetine CR to Apotex.

Mylan
In addition, the District Court ordered Apotex to immediately recall all product from its direct customers that was shipped since the injunction was entered on July 16, 2014.

Mylan has an exclusive license to an Orange Book patent pertaining to Paxil CR which expires in July 2016, with pediatric exclusivity extending until Jan. 19, 2017. Mylan further believes that it is the only company to have filed an abbreviated new drug application for generic Paxil CR that contains a paragraph IV certification.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

Logo - http://photos.prnewswire.com/prnh/20140423/77793

SOURCE Mylan Inc.


Quelle: PR Newswire  

http://www.ariva.de/news/...EPS-of-0-69-In-Line-With-Guidance-5126905 GrB  

http://www.ariva.de/news/Mylan-Launches-Generic-Xeloda-Tablets-5130077 GrB  

http://www.ariva.de/news/...tion-Another-Key-Product-Approval-5139029 GrB  

http://www.ariva.de/news/...Klor-Con-Extended-Release-Tablets-5142437 GrB  

http://www.ariva.de/news/...eo-About-Anaphylaxis-Preparedness-5143768 GrB  

http://www.ariva.de/news/...-Clinton-Health-Access-Initiative-5232102 GrB  

Kreise: Teva könnte noch am heutigen Dienstag ein feindliches Übernahmeangebot für Mylan vorlegen.

quelle:https://www.boerse-go.de/jandaya/#!Ticker/Profil/Mylan  

Mylan: Teva legt ein Übernahmeangebot zu $82 je Aktie vor  

Argus Research Company hat das Kursziel für Mylan N.V. von 80 auf 85 USD angehoben, aber die Einstufung auf "Buy" belassen.  

Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance  

Und der Kurs startet durch was sonst ? ;-)  

So eine günstige Bewertung in der Branche. Was stimmt nicht?  

Schwer zu sagen warum Mylan so dahin duempelt. Wobei pharma momentan ingesamt eher schlecht laeuft. Was bei Mylan allerdings fehlt ist Dividende da gibts nichts und da gabs nichts, komisch da verdient man angeblich gut ist jetzt auch keine kleine klitsche und dann bleibt fuer die Aktionaere nichts.  

Mylan meldet Zahlen für 2018

• Umsatz 11,4 Mrd. $
  
• Gewinn 353 Mio. $
  
• EPS 0,68$
  
  • 2019-er Ausblick: Umsatz 11,5-12,5 Mrd. $
    

http://investor.mylan.com/news-releases/...full-year-2018-results-and

 

Wenn mann sich die Zahlen genau anschaut, aufgerundet 400 mio gewinn mktkp ca 30 mrd ne gibt kein gutes Kgv warum also mylan kaufen oder halten, wenn auch noch der Aysblick schlecht ist.  

Mktkp ist wohl nur noch ca 15 mrd das macht die Situation schon ein bisschen besser  

Mylan meldet Zahlen für Q1/19

• Umsatz 2,5 Mrd. $
  
• Verlust 25 Mio. $
  
• adj. Gewinn 422 Mio. $
  
• Ausblick bestätigt
  
• MK 11,3 Mrd. $
  

http://investor.mylan.com/news-releases/...results-and-reaffirms-2019